Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kronos Bio, Inc. - Common Stock (NQ:KRON)

0.7105 -0.0195 (-2.67%)
Streaming Delayed Price Updated: 3:48 PM EDT, May 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kronos Bio, Inc. - Common Stock

< Previous 1 2 Next >
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNB, COLB, KRON on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancorp, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders
From Ademi & Fruchter LLP
Via Business Wire
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces CEO Transition and Reduction in Force
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – 
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in Medical and Investor Conferences in September
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Reports First-Quarter 2024 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
Company eliminates three executive officer roles and appoints new Executive Leadership team 
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
From Kronos Bio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.